ClinicalTrials.gg
Drug

CPX-351 clinical trials

Also written CPX-351.

studies test it
63
open now
17
in phase 3
6
first study started
2008

How each study uses CPX-351 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the CPX-351 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Vyxeos
36
Liposome-encapsulated Daunorubicin-Cytarabine
22
Cytarabine-Daunorubicin Liposome for Injection
19
Liposomal AraC-Daunorubicin CPX-351
18
Liposomal Cytarabine-Daunorubicin
18

Development codes

CPX-351
54

Studies by the year they started

62 studies that test it; most in 2019 (13); 1 more planned to start later

Studies that test CPX-351, by start year
YearStudies
20081
20092
20122
20132
20143
20152
20161
20172
20186
201913
20209
20215
20224
20235
20244
20251

By phase

A phase 1/2 study counts in both.

Phase 1
26
Phase 2
42
Phase 3
6
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 55

M.D. Anderson Cancer Center (7) · Jazz Pharmaceuticals (7) · Weill Medical College of Cornell University (4) · Fred Hutchinson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · Case Comprehensive Cancer Center (2)

Often tested with

Tested in the same studies.

Cytarabine (6) · Venetoclax (6) · Gemtuzumab (4) · Azacitidine (4) · Fludarabine (3) · Gilteritinib (3) · Quizartinib (2) · Busulfan (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 1 in phase 3

Studies that test CPX-351, phase 3 first.

Studies

Open first, then newest update. How each study uses CPX-351 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 63

See all 63 studies that test CPX-351 →

Given beside what is tested · 5 — CPX-351 is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with CPX-351

Codes

What other systems call CPX-351 · ClinicalTrials.gg INT001046

  • MeSH (NLM) C000629812CPX-351One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.